Patel declared that under the leadership of President Trump and Vice President Vance, America’s immigration policy would once again become a beacon of hope for the world. However, he reminded ...

The Senate Judiciary Committee will hold a hearing for President Donald Trump's nomination for FBI director, Kash Patel, next week, says the panel's top Democrat, Illinois Sen. Dick Durbin. Durbin ...

Among a myriad of reasons, one factor that has remained a defining factor for success for many is the brand's authenticity. Priti Singh, a founder, beautypreneur, and the heart and soul behind the ...

“Kash Patel has neither the experience, the temperament, nor the judgment to lead the FBI,” Durbin said in a statement after a 30-minute meeting with Patel.… ...

“There are limited treatment options and a significant unmet need for patients with advanced melanoma who previously received an anti-PD-1 containing regimen,” said Sushil Patel, Ph.D., Chief ...

Mr Adani, his wife, Priti Adani, who is the Chairperson of the Adani Foundation, and son, Karan Adani, the Managing Director of Adani Ports and SEZ Limited (APSEZ), also offered prayers at Triveni ...

The 62-year-old billionaire was accompanied by his wife, Priti Adani. Gautam Adani and family offered prayers at the Triveni Sangam at Maha Kumbh(ANI) The Adani Group has partnered with ISKCON to ...

US President Donald Trump eventually plans to nominate Kash Patel as the new FBI director, though at the same time, his Senate confirmation hearing has not yet been scheduled, asserted Fox News. Kash ...

Priti Patel. There could be a less malign interpretation of Trump’s interest in the international, and especially the European, right – less malign, that is, in Trump’s view. Might it not be ...

“There are limited treatment options and a significant unmet need for patients with advanced melanoma who previously received an anti-PD-1 containing regimen,” said Sushil Patel, Ph.D., Chief ...

Sushil Patel, Ph.D., Chief Executive Officer of Replimune, highlighted the importance of this milestone, noting the limited treatment options available for advanced melanoma patients who have ...

WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...